Short answer
Edwards Lifesciences (EW) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Theodora Mistras becomes CFO May 29, 2026, succeeding Scott B. Ullem.
Edwards Lifesciences 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Theodora Mistras becomes CFO May 29, 2026, succeeding Scott B. Ullem
- Base salary $925,000 with target annual bonus of at least 100% of salary
- $2.013M sign-on bonus, repayable pro rata after voluntary departure or misconduct termination within 24 months
- Initial RSU award valued at $8M, primarily vesting over two years
- Fiscal 2026 annual equity award valued at $4.5M, plus severance and change-in-control protections
Item 7.01 · Regulation FD Disclosure
- Ms. Mistras appointed Corporate Vice President and Chief Financial Officer effective May 4, 2026
- Leadership transition creates potential investor focus on financial strategy, reporting, and capital allocation
- Press release furnished as Exhibit 99.1 for appointment details and transition terms
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edwards Lifesciences 8-K filings
Get the next EW 8-K as it lands
Follow EW for push alerts, or ask the research agent what this filing means.